Overactive Bladder Clinical Trial
Official title:
The Effect of an Additional TVT on OAB Symptoms in Surgical Repair of Pelvic Organ Prolapse
Verified date | August 2017 |
Source | Icahn School of Medicine at Mount Sinai |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Pelvic organ prolapse (POP) is a common condition in women. Approximately 20% of women
undergo surgical correction for POP in their lifetime. Overactive bladder symptoms (OAB) are
often associated with POP in 25-69% of patients and POP has been shown to be an independent
risk factor for OAB. There is scientific evidence that surgical repair of POP reduces or
eliminates OAB in >85%. In addition, stress urinary incontinence (SUI) is also often
associated with POP, either clinically evident or as a potential post-operative complication.
The clinical decision as to include a surgical technique to treat SUI when repairing POP
surgically is still a matter of controversy. Most surgeons at the institution will include an
extra procedure, specifically a retropubic sling, if SUI is clinically evident. Some will not
include it unless there is urodynamic or clinical evidence of potential SUI post-operatively.
Finally, some will include it regardless of clinical or urodynamic findings based on the
apparent high incidence of such SUI after prolapse repair. The Tension-Free-Vaginal Tape
(TVT) has been observed to reduce OAB as well as produce de-novo OAB symptoms, so the effect
of TVT on OAB is still unclear.
The purpose of this study is to determine the effect of additional TVT surgery on OAB
symptoms in patients undergoing POP repair. It is hoped that such data will better determine
the effect of either surgical intervention strategy on OAB symptoms. This is a prospective
cohort study comparing patients with OAB that undergo surgical repair of their prolapse with
or without additional TVT surgery. The outcomes will be measured using pre- and
post-operative validated questionnaires (PFDI-20, OAB-q short form).
Status | Completed |
Enrollment | 40 |
Est. completion date | June 30, 2017 |
Est. primary completion date | June 30, 2017 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Female |
Age group | 22 Years and older |
Eligibility |
Inclusion Criteria: - Women >21 years old with stage 2 or greater pelvic organ prolapse who plan to undergo anterior and/or apical prolapse repair - Women who respond affirmatively to questions 15 and 16 on the PFDI-20 questionnaire - Women with negative urine culture pre-operatively - Women able to provide informed consent Exclusion Criteria: - Women with pelvic organ prolapse that respond negatively to questions 15 and 16 on the PFDI-20 questionnaire - Women with previous urogynecologic surgery including prior hysterectomy with any type of apical support known to the patient (history of hysterectomy alone may be included) - Women who report UTI within 1 month of recruitment (with confirmation of positive culture) - Women with history of diagnosis of interstitial cystitis or any treatment for interstitial cystitis - Women who undergo TVT-O (transobturator) and not retropubic TVT - Women who undergo posterior compartment repair only - Women who are pregnant and up to 6 weeks postpartum - Women who undergo prolapse repair with transvaginal mesh |
Country | Name | City | State |
---|---|---|---|
United States | Mount Sinai Hospital | New York | New York |
Lead Sponsor | Collaborator |
---|---|
Icahn School of Medicine at Mount Sinai |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Overactive Bladder Questionnaire (OAB-q short form) | Change in the OAB-q score at 6 weeks as compared to baseline. The OAB-q short form is a validated questionnaire which includes a 6-item symptoms bother scale (OAB-q ss) and a 13-item HRQL scale (OAB-q HRQL) | baseline and 6 weeks | |
Primary | Overactive Bladder Questionnaire (OAB-q short form) | Change in the OAB-q score at 6 months as compared to baseline. | baseline and 6 months | |
Primary | Overactive Bladder Questionnaire (OAB-q short form) | Change in the OAB-q score at 12 months as compared to baseline. | baseline and 12 months | |
Secondary | UDI-6 change score | Change in the UDI-6 score at 6 weeks as compared to baseline. UDI-6 is a validated questionnaire pertaining to urinary symptoms. It is based on a 5 point scale- 0 for no, and then in terms of how bothersome symptoms are 2- not at all, 3- somewhat, 4- moderately, 5- quite a bit. | baseline and 6 weeks | |
Secondary | UDI-6 change score | Change in the UDI-6 score at 6 months as compared to baseline. | baseline and 6 months | |
Secondary | UDI-6 change score | Change in the UDI-6 score at 12 months as compared to baseline. | baseline and 12 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04578899 -
"The Effectiveness of Transvertebral Magnetic Neuromodulation in Patients With Detrusor Overactivity"
|
N/A | |
Active, not recruiting |
NCT03556891 -
Pivotal Study of eCoin for Overactive Bladder With Urgency Urinary Incontinence
|
N/A | |
Not yet recruiting |
NCT05977634 -
Transcutaneous Tibial Nerve Stimulation for Idiopathic Overactive Bladder
|
N/A | |
Completed |
NCT01955408 -
Severity of Overactive Bladder Symptoms in Patients After Synergo Treatment
|
N/A | |
Recruiting |
NCT06201013 -
Efficacy and Safety of Vitamin D in the Treatment of OAB-wet in Children
|
N/A | |
Recruiting |
NCT03727711 -
TPTNS: Home vs Hospital Treatment for Overactive Bladder
|
N/A | |
Completed |
NCT00768521 -
A Study to Test the Effects of Tolterodine Tartrate in Patients With Overactive Bladder (0000-107)
|
Phase 1 | |
Completed |
NCT03625843 -
Mindfulness Exercises to Reduce Anxiety and Pain During Urodynamic Testing
|
N/A | |
Completed |
NCT02211846 -
A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Mirabegron OCAS (Oral Controlled Absorption System) in Pediatric Subjects With Neurogenic Detrusor Overactivity or Overactive Bladder
|
Phase 1 | |
Completed |
NCT02835846 -
Investigation of the Effect of the Female Urinary Microbiome on Incontinence
|
Phase 4 | |
Completed |
NCT02857816 -
PRospective Study to Evaluate EffectivenesS With the NURO™ PErcutaneous Tibial Neuromodulation System in Patients With OAB
|
N/A | |
Completed |
NCT02202031 -
Controlling Urgency Through Relaxation Exercises
|
N/A | |
Withdrawn |
NCT02320201 -
Foot Neuromodulation for Overactive Bladder in Children
|
N/A | |
Completed |
NCT01458197 -
A Phase 2 Study to Compare the Efficacy and Tolerability of Tarafenacin 0.2 mg and Tarafenacin 0.4 mg to Placebo in Patients Suffering From Overactive Bladder.
|
Phase 2 | |
Not yet recruiting |
NCT01409512 -
Evaluation of Autonomic System Before and After Anticholinergic Treatment in Women With Overactive Bladder
|
N/A | |
Completed |
NCT01437670 -
Observational Study to Estimate the Dry Mouth in OAB Patients With Solifenacin
|
N/A | |
Not yet recruiting |
NCT01423838 -
Comparison of Solifenacin and Oxybutynin in the Treatment of Overactive Bladder
|
Phase 4 | |
Terminated |
NCT01758848 -
Physical Therapy for Overactive Bladder
|
N/A | |
Withdrawn |
NCT01210859 -
Effects of Antimuscarinic Drugs on Overactive Bladder (OAB) Symptoms After Insertion of Ureteral Stents
|
N/A | |
Completed |
NCT01122550 -
Reproducibility Study of Overactive Bladder Symptom Score [OABSS]
|
N/A |